- Health Secretary Robert F. Kennedy Jr. announced a new policy allowing the widespread use of six unapproved peptide injection compounds without facing HHS enforcement action.
- The policy change overrides previous FDA warnings and was implemented despite opposition and minimal input from FDA scientists.
- HHS argued the shift promotes patient choice and provides a safer alternative to unregulated foreign peptides, though the department acknowledged compounded drugs can pose health risks.
- While the policy requires patient-specific prescriptions, traceable ingredients, and safety reporting, it does not grant formal FDA approval or establish clinical efficacy.
- Kennedy, who previously praised peptides on Joe Rogan's podcast after using them for injuries, framed the policy shift as a win for health freedom under the Trump administration.
IN FULL
